| Title: |
Safety of Intradialytic Bamlanivimab/Etesevimab Administration in Two COVID-19 Dialysis Outpatients |
| Authors: |
Gasperoni, Lorenzo; Abenavoli, Chiara; Donati, Gabriele; Scrivo, Anna; Zappulo, Fulvia; Cingolani, Alessandra; Hu, Lilio; La Manna, Gaetano |
| Source: |
Blood Purification ; volume 51, issue 10, page 875-878 ; ISSN 0253-5068 1421-9735 |
| Publisher Information: |
S. Karger AG |
| Publication Year: |
2022 |
| Description: |
Chronic hemodialysis patients are at high risk of severe COVID-19 disease and death related to the infection. Anti-spike monoclonal antibodies administration reduces risk of disease progression and hospitalization in high-risk subjects but no clear data on end-stage renal disease are available. We report 2 cases of Bamlanivimab/Etesevimab administration to two not hospitalized chronic hemodialysis patients with SARS-CoV2 infection. Since they are large molecules (human immunoglobulin G1) with molecular weight of 146,000 Da, administration was conducted during the second hour of the dialysis session with no adverse reaction. Conclusions: Intradialytic administration of Bamlanivimab/Etesevimab could be considered safe and may allow adequate clinical observation time without hospital-stay prolongation. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1159/000521637 |
| Availability: |
https://doi.org/10.1159/000521637; https://www.karger.com/Article/Pdf/521637 |
| Rights: |
https://www.karger.com/Services/SiteLicenses ; https://www.karger.com/Services/SiteLicenses |
| Accession Number: |
edsbas.427A6609 |
| Database: |
BASE |